KAISER ALUMINUM CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that KAISER ALUMINUM CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $389.40M | Feb 22, 2019 |
| FY2018 | Sep 30, 2018 | $393.10M | Feb 22, 2019 |
| FY2018 | Jun 30, 2018 | $415.40M | Feb 22, 2019 |
| FY2018 | Mar 31, 2018 | $388.00M | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $353.10M | Feb 22, 2019 |
| FY2018 | Sep 30, 2017 | $332.80M | Feb 22, 2019 |
| FY2018 | Jun 30, 2017 | $356.30M | Feb 22, 2019 |
| FY2018 | Mar 31, 2017 | $355.30M | Feb 22, 2019 |
| FY2018 | Dec 31, 2016 | $1.33B | Feb 22, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.37B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.02B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.09B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $3.43B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $2.62B | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $1.17B | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $368.70M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $374.90M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $375.30M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $395.20M | Feb 25, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $70.70M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $76.30M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $71.80M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $80.10M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $72.10M | Feb 25, 2020 |
| FY2019 | Sep 30, 2018 | $69.80M | Feb 25, 2020 |
| FY2019 | Jun 30, 2018 | $72.00M | Feb 25, 2020 |
| FY2019 | Mar 31, 2018 | $71.30M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | $75.90M | Feb 22, 2019 |
| FY2018 | Sep 30, 2017 | $76.40M | Feb 22, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $112.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $65.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $67.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($29.60M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($18.50M) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $28.80M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | ($10.60M) | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $25.40M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $19.20M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $28.00M | Feb 25, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $188.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $112.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $122.50M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $4.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $64.40M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $81.10M | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | $9.60M | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | $40.70M | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | $32.40M | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | $43.00M | Feb 25, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.70M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $12.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $11.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $9.30M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $9.30M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $9.10M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $10.50M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $9.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $10.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $10.20M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $111.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $167.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $211.90M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($63.10M) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $79.40M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $206.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $232.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $150.20M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $141.50M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $165.60M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.56B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $2.41B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $2.27B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $2.29B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $2.42B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.86B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $1.53B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.42B | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | $1.40B | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $1.39B | Feb 22, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.67B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.62B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $1.66B | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $1.73B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.13B | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $792.30M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $678.90M | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | $640.40M | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $638.90M | Feb 22, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $826.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $743.10M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $708.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $631.20M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $692.50M | Feb 20, 2025 |
| FY2023 | Dec 31, 2020 | $732.40M | Feb 23, 2024 |
| FY2022 | Dec 31, 2019 | $733.90M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | $740.40M | Mar 1, 2022 |
| FY2018 | Jan 1, 2018 | $756.40M | Feb 22, 2019 |
| FY2020 | Dec 31, 2017 | $746.30M | Feb 26, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.80M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $18.80M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $18.80M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $18.80M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $39.30M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $18.80M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $18.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $44.00M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $18.80M | Feb 25, 2020 |
| FY2017 | Dec 31, 2016 | $37.20M | Feb 23, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $142.50M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $81.30M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $66.30M | Feb 19, 2026 |
| FY2023 | Dec 31, 2022 | $13.30M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | $93.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $158.20M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $172.80M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $150.20M | Feb 25, 2020 |
| FY2018 | Jan 1, 2018 | $95.60M | Feb 22, 2019 |
| FY2018 | Dec 31, 2017 | $85.50M | Feb 22, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $18.40M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $82.40M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $57.40M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $303.20M | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | $780.30M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $264.30M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $125.60M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $51.10M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $55.20M | Feb 22, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $4.70M | Feb 29, 2012 |
| FY2011 | Dec 31, 2010 | $13.10M | Feb 29, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 1 | Feb 25, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 6 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | 4 | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | (1) | Feb 23, 2024 |
| FY2022 | Dec 31, 2020 | 1 | Feb 24, 2023 |
| FY2019 | Dec 31, 2019 | 0 | Feb 25, 2020 |
| FY2019 | Sep 30, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Jun 30, 2019 | 1 | Feb 25, 2020 |
| FY2019 | Mar 31, 2019 | 1 | Feb 25, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 16.21M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 16.10M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 16.02M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | 15.94M | Feb 23, 2024 |
| FY2022 | Dec 31, 2021 | 15.87M | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | 15.81M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 15.87M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 16.23M | Feb 25, 2020 |
| FY2018 | Dec 31, 2017 | 16.77M | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | 17.65M | Feb 23, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $39.40M | Feb 25, 2020 |
| FY2019 | Dec 31, 2018 | $37.70M | Feb 25, 2020 |
| FY2019 | Dec 31, 2017 | $35.00M | Feb 25, 2020 |
| FY2018 | Dec 31, 2016 | $32.40M | Feb 22, 2019 |
| FY2017 | Dec 31, 2015 | $28.10M | Feb 23, 2018 |
| FY2016 | Dec 31, 2014 | $25.40M | Feb 22, 2017 |
| FY2015 | Dec 31, 2013 | $23.00M | Feb 22, 2016 |
| FY2014 | Dec 31, 2012 | $19.60M | Feb 20, 2015 |
| FY2013 | Dec 31, 2011 | $18.90M | Feb 18, 2014 |
| FY2012 | Dec 31, 2010 | $19.00M | Feb 21, 2013 |